Clinical trials: Inflammatory Disease
Osteoarthritis, Knee, Osteoarthritis, Hip
Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
The primary objective of the study is to evaluate the efficacy of fasinumab compared to placebo, when administered for up to 24 weeks in patients with pain due to osteoarthritis (OA) of the knee or hip.
- Trial name
- FACT OA2 (NCT03304379)
- Testing
- Fasinumab, Diclofenac, Celecoxib
- Where
- 71 sites in United States
- Volunteers
- 1,650 people
- Sponsor
- Regeneron Pharmaceuticals
Colon Cancer, Colon Polyp
Virtual Incision Robotically Assisted Surgical Device Use in Minimally Invasive Colectomy
For patients with colon polyps (clumps of cells in the lining of the colon) treatment often requires removal of the affected portion of the colon.
- Conditions
- Colon Cancer, Colon Polyp, Diverticular Diseases, Inflammatory Bowel Diseases
- Trial name
- NCT04703829
- Testing
- VI-RASD use in minimally invasive right or left colectomy, Right or Left colectomy
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Virtual Incision Corporation
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathies(IIM)
A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
This is a prospective, single-arm, open-label and dose-escalation investigator initialed study to evaluate LUCAR-G79D in adult subjects with r/r SLE and r/r IIM.
- Trial name
- NCT07331272
- Testing
- LUCAR-G79D T cells
- Where
- 5 sites in China
- Volunteers
- 38 people
- Sponsor
- Nanjing Legend Biotech Co.
Ulcerative Colitis
An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)
Ulcerative colitis (UC) is a chronic, relapsing, and incurable inflammatory disease of the large intestine. The hallmark clinical symptoms include bloody diarrhea associated with rectal urgency and tenesmus..
- Trial name
- NCT06838845
- Where
- 3 sites in China
- Volunteers
- 80 people
- Sponsor
- AbbVie
Ulcerative Colitis
Phase II Study of HMPL-004 in Patients With Ulcerative Colitis
The purpose of this study is to evaluate the safety and efficacy of HMPL-004 in patients with active mild to moderate ulcerative colitis (UC), compared with placebo.
- Trial name
- NCT00659802
- Testing
- HMPL-004 low dose, HMPL-004 high dose
- Volunteers
- 224 people
- Sponsor
- Hutchison Medipharma Limited
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Gram-negative Bacterial Infections, Bloodstream Infections (BSI)
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants
The primary objectives of this study are: To assess the safety and tolerability of cefiderocol after single-dose administration in hospitalized paediatric participants 3 months to < 18 years of age with suspected or confirmed…
- Conditions
- Gram-negative Bacterial Infections, Bloodstream Infections (BSI), Complicated Intra-abdominal Infection (cIAI), Hospital Acquired Pneumonia (HAP)
- Trial name
- NCT04335539
- Testing
- Cefiderocol, Standard of Care
- Where
- 23 sites in Belgium, Estonia and 7 more
- Volunteers
- 53 people
- Sponsor
- Shionogi
Crohn Disease (CD)
Evaluation of the Acceptability and Therapeutic Maintenance After Substitution of Ustekinumab With a Biosimilar
In a population of adult patients followed for Crohn's disease, who had previously agreed to replace Stelara® with a biosimilar of ustekinumab (Uzpruvo®) and were followed over a period of 12 months under usual medical practice…
- Trial name
- NCT07077681
- Where
- 11 sites in France
- Volunteers
- 246 people
- Sponsor
- EG Labo
Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe
PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)
The purpose of the study is to evaluate the safety, tolerability, and clinical efficacy of PN-943 450 mg twice daily [BID] and PN-943 150 mg BID, compared with placebo BID, in subjects with moderate to severe active Ulcerative…
- Trial name
- NCT04504383
- Testing
- PN-943
- Where
- 122 sites in United States, Austria and 11 more
- Volunteers
- 169 people
- Sponsor
- Protagonist Therapeutics, Inc.
Breast Cancer
A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.
This single arm study will assess the efficacy and safety of preoperative treatment with Avastin combined with Herceptin-based chemotherapy in patients with primary inflammatory HER2-positive breast cancer.
- Trial name
- NCT00717405
- Testing
- Standard chemotherapy, bevacizumab [Avastin], trastuzumab [Herceptin]
- Where
- 28 sites in France
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Ulcerative Colitis (UC), UC - Ulcerative Colitis
Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the clinical efficacy and safety of OD-07656 in participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- NCT06850727
- Testing
- OD-07656, Vedolizumab
- Where
- 32 sites in Australia, Austria and 8 more
- Volunteers
- 57 people
- Sponsor
- Odyssey Therapeutics, Inc.
Colitis, Ulcerative
A Study to Evaluate the Safety, Tolerability, PK and Preliminary Efficacy of HX15001 Combined With Etrasimod in Moderate-severe Ulcerative Colitis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HX15001 injection combined with Etrasimod tablets in participants with moderately to severely active ulcerative…
- Trial name
- NCT07768254
- Testing
- Biological: HX15001
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Helixon Biotechnology (Suzhou) Co., Ltd
Healthy, Psoriasis
Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg
The proposed exploratory study aims to understand the in vivo skin distribution properties of subcutaneously (s.c.) administered AIN457 in psoriatic and healthy skin using open flow microperfusion (OFM).
- Trial name
- OFM ISF (NCT01539213)
- Testing
- secukinumab (AIN457)
- Where
- Austria
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Ulcerative Colitis, Crohn's Disease
A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil
The primary reason of this study is to observe current and past treatment in adult participants receiving Vedolizumab, intravenous (IV) or subcutaneous (SC), for IBD in Brazil.
- Trial name
- NCT05626088
- Testing
- No Intervention
- Where
- Brazil
- Volunteers
- 1,006 people
- Sponsor
- Takeda
Crohn's Disease
Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease
This study will evaluate higher versus standard adalimumab dosing regimens for induction and maintenance therapy in subjects with moderately to severely active Crohn's Disease and evidence of mucosal ulceration.
- Trial name
- NCT02065570
- Testing
- Adalimumab
- Where
- 143 sites in United States, Austria and 18 more
- Volunteers
- 514 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
The core and extension studies assessed the safety and efficacy of secukinumab when added to a background therapy in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate response to anti-TNF-α…
- Trial name
- REASSURE (NCT01377012)
- Testing
- Secukinumab (AIN457)
- Where
- 142 sites in United States, Argentina and 14 more
- Volunteers
- 637 people
- Sponsor
- Novartis Pharmaceuticals
Ulcerative Colitis
Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Adults
This study will estimate the absolute bioavailability of subcutaneously injected GS-5745, characterize the safety, tolerability, and pharmacokinetics (PK) of GS-5745 after subcutaneous (SC) injection and intravenous (IV)…
- Trial name
- NCT02209987
- Testing
- GS-5745 SC, GS-5745 IV
- Where
- New Zealand
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Pulmonary Disease, Chronic Obstructive
A Study To Investigate The Ability To Use 18FDG PET Scanning To Monitor The Effectiveness Of New Drugs In COPD Patients
It is hypothesised that there is a difference between the uptake of a radioactive substance ([18F]fluorodeoxyglucose (FDG)) in the lungs of patients with Chronic Obstructive Pulmonary Disease (COPD) and healthy volunteers.
- Trial name
- NCT00472264
- Testing
- PET imaging
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Colitis, Ulcerative
Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).
The purpose of this study is to evaluate serum soluble human ST2 protein, the receptor for Interleukin-33 (IL-33) and a member of the proinflammatory Interleukin-1 (IL-1) receptor superfamily, as a surrogate biological marker…
- Trial name
- EVOLUTION (NCT02318667)
- Testing
- Golimumab
- Volunteers
- 38 people
- Sponsor
- Merck Sharp & Dohme LLC
Ulcerative Colitis
MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients
This is a multi-centre, randomised, double-blind, placebo controlled, parallel group, Phase II study to evaluate efficacy and safety of 3 doses of MEDI7183, in Japanese subjects with moderate to severe UC
- Trial name
- NCT01959165
- Testing
- MEDI7183 low dose, MEDI7183 medium dose, MEDI7183 high dose
- Where
- 23 sites in Japan
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.